Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Kangtai Biological Products Co., Ltd.
  6. News
  7. Summary
    300601   CNE100002Q33

SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

(300601)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

China's Rhodiola set to sell and test Russia's Sputnik-V vaccine

11/11/2020 | 10:12am EDT
FILE PHOTO: FILE PHOTO: A medic of the regional hospital receives  Russia's

HONG KONG/BEIJING (Reuters) - China's Tibet Rhodiola Pharmaceutical Holding announced a deal on Wednesday to manufacture, sell and test Russia's COVID-19 vaccine in China, hours after interim results showed it was 92% effective at protecting people from the disease.

The initial results of the Sputnik V vaccine are only the second to be published from a late-stage human trial in the global effort to produce vaccine that could halt a pandemic that has killed more than 1.2 million people and ravaged the world economy.

Rhodiola said it plans to conduct early and mid-stage trials of the Russian vaccine in China and final-stage trials overseas, although the trials are yet to be approved by regulators.

Rhodiola, currently unable to produce the Russian vaccine, said it would outsource early development and manufacturing work, and would also consider building production lines at its subsidiary.

The deal requires Rhodiola's unit to supply the Russian firm with enough vaccine doses to inoculate at least 20 million people in 2021. It adds to several manufacturing deals Russia has announced so far, including a plan to produce 300 million doses in India.

The agreement would also allow Rhodiola to supply vaccine produced in China to designated buyers overseas.

While China has five vaccines in the final stage of clinical trials, local firms have also partnered with foreign drugmakers to test and distribute front-running vaccines in the country.

Shanghai Fosun Pharmaceutical Group is seeking regulatory approval to trial a product from Pfizer and BioNTech, and Shenzhen Kangtai Biological Products aims to begin human tests for AstraZeneca's candidate this year.

(Reporting by Roxanne Liu and Meg Shen, editing by Louise Heavens and Bernadette Baum)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.11% 8268 Delayed Quote.12.89%
BIONTECH SE 5.04% 328.35 Delayed Quote.302.78%
PFIZER, INC. 0.05% 42.81 Delayed Quote.16.30%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 9.54% 81.88 End-of-day quote.51.66%
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. -3.35% 127 End-of-day quote.-27.22%
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. 0.67% 57.17 End-of-day quote.-15.03%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -0.09% 73.073 Delayed Quote.-0.78%
All news about SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
07/13SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : Kangtai Biological to Issue $309 Million ..
MT
06/22Phase III Clinical Fieldwork of the Inactivated COVID-19 Vaccine (Vero Cells)..
CI
05/31SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : Kangtai Biological to List 1.3 Million Ne..
MT
05/25China's Kangtai Biological, partners agree to run Phase III trial in Chile - ..
RE
05/21Shenzhen Kangtai Biological Products Co., Ltd. Not to Pay Dividend for the Ye..
CI
05/16SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : China Approves Kangtai Biological's COVID..
MT
04/29Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for t..
CI
04/23Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for t..
CI
02/02MARKET CHATTER : Kangtai Biological to Produce 400 Million AstraZeneca COVID-19 ..
MT
02/02ASTRAZENECA : China partner expects to be able to make 400 mln COVID-19 vaccine ..
RE
More news
Financials
Sales 2021 3 618 M 560 M 560 M
Net income 2021 1 137 M 176 M 176 M
Net cash 2021 3 327 M 515 M 515 M
P/E ratio 2021 75,1x
Yield 2021 0,22%
Capitalization 87 243 M 13 502 M 13 503 M
EV / Sales 2021 23,2x
EV / Sales 2022 15,2x
Nbr of Employees 2 043
Free-Float 95,6%
Chart SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Shenzhen Kangtai Biological Products Co., Ltd. Technical Analysis Chart | 300601 | CNE100002Q33 | MarketScreener
Technical analysis trends SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 127,00 CNY
Average target price 230,56 CNY
Spread / Average Target 81,5%
EPS Revisions
Managers and Directors
Wei Min Du Chairman & General Manager
Xiang Miao Chief Financial Officer & Board Secretary
Zhi Yun Lu Chairman-Supervisory Board
Xiang Ming Li Independent Director
Dong Guang Ma Independent Director
Sector and Competitors